Advaxis to upgrade preliminary data on ADXS-HPV Stage 2 trial for cervical cancer Advaxis.

In preliminary data to be provided by Dr. Robert Petit, VP of Clinical Medical and Operations Affairs at Advaxis, by May 18, 2012: 109 patients have received 255 doses of ADVS-HPV, The tolerability of ADXS-HPV weighed against one agent and favorably combination chemotherapies active in this disease establishing, with 36 percent of patients experiencing Grade 1-2 adverse occasions related/possibly related to ADXS-HPV and 0.9 percent experiencing a Grade 3 serious adverse event, Survival at 6, 9, and 12 a few months is definitely 65 percent, 40 percent, and 31 percent, respectively. Related StoriesStudy shows uncommon HER2 missense mutations usually do not spread breast cancer on the ownNew results reveal association between colorectal cancer and melanoma medication treatmentFDA grants accelerated acceptance for Tagrisso to take care of patients with advanced NSCLC While the primary clinical advantage expected from immunotherapy is normally overall survival , it is encouraging that objective tumor regressions in response to therapy have been observed.AIDS Breakthroughs: Big Gains in HIV Fight It had been a big month in the ongoing fight against HIV/AIDS, with major Helps breakthrough announcements weekly coming almost. Fourteen days ago, researchers proclaimed these were able to isolate human being antibodies that can neutralize 90 % of the HIV mutations that trigger AIDS. They believe their analysis might lead to a vaccine. Last week, the US reportedthat the number of young people contaminated with HIV dropped by at least twenty five % in twelve Africa countries. And now, scientists say they have a new vaginal gel that is partially capable of blocking the Helps virus and can cut a woman’s likelihood of contracting HIV from an infected partner in half.